Sheethal Jose

Sheethal Jose

Auto-generated profile, based on publicly available information

Sheethal Jose

Berman Institute of Bioethics, Johns Hopkins University, 1809 Ashland Avenue, Baltimore, MD, 21205, United States, 1 410-614-5634

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
HZHana Zouk
Hana Zouk
EVEric Venner
Eric Venner
NLNiall J. Lennon
Niall J. Lennon
DMDonna M. Muzny
Donna M. Muzny
DADebra Abrams
Debra Abrams
RGRichard A. Gibbs
Richard A. Gibbs

24 May 2017 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
MSMarta E. Stremska
Marta E. Stremska
SJSheethal Jose
Sheethal Jose
VSVikram Sabapathy
Vikram Sabapathy
LHLiping Huang
Liping Huang
ABAmandeep Bajwa
Amandeep Bajwa
RSRahul Sharma
Rahul Sharma
CD4+Foxp3+ regulatory T cells (Tregs) protect the kidney during AKI. We previously found that IL-2, which is critical for Treg homeostasis, upregulates the IL-33 receptor (ST2) on CD4+ T cells, thus we hypothesized that IL-2 and IL-33 cooperate to enhance Treg function. We found that a major subset of Tregs in mice express ST2, and coinjection of IL-2 and IL-33 increased the number of Tregs in lymphoid organs and protected mice from ischemia-reperfusion injury (IRI) more efficiently than either cytokine alone. Accordingly, we generated a novel hybrid cytokine (IL233) bearing the activities of IL-2 and IL-33 for efficient targeting to Tregs. IL233 treatment increased the number of Tregs in blood and spleen and prevented IRI more efficiently than a mixture of IL-2 and IL-33. Injection of IL233 also increased the numbers of Tregs in renal compartments. Moreover, IL233-treated mice had fewer splenic Tregs and more Tregs in kidneys after IRI. In vitro, splenic Tregs from IL233-treated mice suppressed CD4+ T cell proliferation better than Tregs from saline-treated controls. IL233 treatment also improved the ability of isolated Tregs to inhibit IRI in adoptive transfer experiments and protected mice from cisplatin- and doxorubicin-induced nephrotoxic injury. Finally, treatment with IL233 increased the proportion of ST2-bearing innate lymphoid cells (ILC2) in blood and kidneys, and adoptive transfer of ILC2 also protected mice from IRI. Thus, the novel IL233 hybrid cytokine, which utilizes the cooperation of IL-2 and IL-33 to enhance Treg- and ILC2-mediated protection from AKI, bears strong therapeutic potential.

1 November 2018 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
Iftikhar KulloIftikhar Kullo
Iftikhar Kullo
JOJanet Olson
Janet Olson
XFXiao Fan
Xiao Fan
MJMerin Jose
Merin Jose
MSMaya Safarova
Maya Safarova
STStephen N. Thibodeau
Stephen N. Thibodeau

1 August 2019 in Journal of Autoimmunity
Verified
Journal Article
Closed access
MSMarta E. Stremska
Marta E. Stremska
CDChao Dai
Chao Dai
RVRajkumar Venkatadri
Rajkumar Venkatadri
HWHongyang Wang
Hongyang Wang
VSVikram Sabapathy
Vikram Sabapathy
RSRahul Sharma
Rahul Sharma

11 April 2025 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
JSJeremy Sugarman
Jeremy Sugarman
JBJuli Bollinger
Juli Bollinger
JAJose Agostini
Jose Agostini
KWKevin Weinfurt
Kevin Weinfurt
GGGail Geller
Gail Geller
TSTravis Sanchez
Travis Sanchez
Background: Molecular HIV surveillance (MHS) can be used to help identify and respond to emerging clusters of rapidly spreading HIV transmissions, a practice known as cluster detection and response (CDR). In the United States, MHS relies on HIV gene sequences obtained from routine clinical antiretroviral resistance testing (ARVRT). By law, ARVRT results are reported to public health agencies for MHS and individuals are not asked for their specific consent to do so. This practice has raised ethical concerns, including the lack of consent for, and transparency surrounding, public health uses of these clinical data. Such concerns have spurred debate and could have a chilling effect on the willingness of people living with HIV to agree to ARVRT when recommended clinically and jeopardize the utility of MHS-informed HIV prevention efforts. In response to the lack of routine disclosure of use of ARVRT results for MHS, in 2022, the Presidential Advisory Council on HIV/AIDS (PACHA) issued a resolution calling on the US Centers for Disease Control to “require that providers explain MHS/CDR and the laboratory test results that are collected and used in these surveillance activities to their patients.” Objective: This study aimed to examine the effect of clinician disclosure of the public health uses of ARVRT results for MHS versus clinician nondisclosure on patient willingness to undergo recommended ARVRT. Methods: We conducted a randomized survey experiment examining the effect of clinician disclosure of the public health uses of ARVRT results for MHS versus clinician nondisclosure (the current standard of care) and subsequent discovery of such uses through a “trusted media source” on patient willingness to undergo recommended ARVRT. Study participants were respondents to 1 of 2 national web-based surveys conducted annually in the United States: the American Men’s Internet Survey (AMIS) and the Transgender Women’s Internet Survey and Testing (TWIST). Results: Overall, 4348 AMIS participants (n=2151 disclosure; n=2197 nondisclosure) and 3314 TWIST participants (n=1670 disclosure; n=1644 nondisclosure) completed survey items regarding the randomly assigned vignettes. The majority were willing to undergo ARVRT regardless of which vignette they saw (1670/2151, 82.7% [AMIS] and 1326/1670, 80.8% [TWIST] in the disclosure group; and 1399/2197, 68% [AMIS] and 1101/1674, 68.45% [TWIST] in the nondisclosure group) after later learning about public health uses of ARVRT results. Conclusions: The majority of respondents expressed willingness to undergo ARVRT even with disclosure of public health uses of these data, but willingness markedly decreased when learning about these uses after the fact, highlighting the importance of transparency in MHS programs. Accordingly, in line with the ethical principle of respect for autonomy and the likelihood that the potential public health benefits of MHS programs will not be compromised, consideration should be given to encouraging clinicians to disclose public health uses of ARVRT at the time ARVRT is recommended.

17 November 2023 in Human Genetics and Genomics Advances
Verified
Journal Article
Open access
SJSheethal Jose
Sheethal Jose
GGGail Geller
Gail Geller
JBJuli Bollinger
Juli Bollinger
DMDebra Mathews
Debra Mathews
JKJeffrey Kahn
Jeffrey Kahn
BGBrian T. Garibaldi
Brian T. Garibaldi
Several genetic variants linked to COVID-19 have been identified by host genomics researchers. Further advances in this research will likely play a role in the clinical management and public health control of future infectious disease outbreaks. The implementation of genetic testing to identify host genomic risk factors associated with infectious diseases raises several ethical, legal, and social implications (ELSIs). As an important stakeholder group, health professionals can provide key insights into these ELSI issues. In 2021, a cross-sectional online survey was fielded to US health professionals. The survey explored how they view the value and ethical acceptability of using COVID-19 host genomic information in three main decision-making settings: (1) clinical, (2) public health, and (3) workforce. The survey also assessed participants' personal and professional experience with genomics and infectious diseases and collected key demographic data. A total of 603 participants completed the survey. A majority (84%) of participants agreed that it is ethically acceptable to use host genomics to make decisions about clinical care and 73% agreed that genetic screening has an important role to play in the public health control of COVID-19. However, more than 90% disagreed that it is ethically acceptable to use host genomics to deny resources or admission to individuals when hospital resources are scarce. Understanding stakeholder perspectives and anticipating ELSI issues will help inform policies for hospitals and public health departments to evaluate and perhaps adopt host genomic technologies in an ethically and socially responsible manner during future infectious disease outbreaks.